FindTrial
Sign In

Effect of Alpha Lipoic Acid on Prevention of Diabetic Peripheral Neuropathy

Role of Oral Alpha Lipoic Acid in Prevention of Diabetic Peripheral Neuropathy â?? A Randomized Control Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/054908
Enrollment
114
Registered
2023-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: alpha lipoic acid: Intervention group will receive alpha lipoic acid 600mg daily dose for 5 weeks,health education regarding life style modification and Vitamin D supplementation of 60,

Sponsors

Tanuja P Pattankar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Known type 2 diabetics diagnosed at least one year prior to the commencement of study.

Exclusion criteria

Exclusion criteria: Patients with type 1 DM, Gestational DM and critically ill patients.

Design outcomes

Primary

MeasureTime frame
Reduction in the score of Total Symptom Score (TSS)Timepoint: At Baseline and end of 6 weeks—

Secondary

MeasureTime frame
To assess the reduction in total symptom score of Diabetic peripheral neuropathy after the intervention with alpha lipoic acid which is an anti - oxidant seems to delay or reverse peripheral diabetic neuropathy at the begining of the study, after 5 weeks and after 3 months.Timepoint: baseline data, after 5 weeks, after 3 months.—

Countries

India

Contacts

Public ContactTanuja P Pattankar

BLDE DU Shri B M Patil medical College hospital and Research Centre Vijayapura

tanuja.pattankar@bldedu.ac.in9008581280

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026